Pathological findings and prognostic factors in recurrent glioblastomas
- 14 February 2012
- journal article
- Published by Springer Nature in Brain Tumor Pathology
- Vol. 29 (4) , 192-200
Abstract
Glioblastomas, which are the most common primary intracranial tumor, are associated with the poorest survival time, which is typically 1–2 years. Age at initial diagnosis, Karnofsky performance score, and O6-methylguanine DNA-methyltransferase (MGMT) promoter methylation status are the most well-documented predictors of survival in patients with newly diagnosed glioblastoma. Few studies have examined prognostic factors in patients with recurrent glioblastomas. At relapse, the pathological features of glioblastomas are affected by tumor regrowth and the influence of chemoradiotherapy during the initial treatment. Morphological transformations at recurrence include quantitative changes in tumor cells, such as the presence of giant cells and gemistocytic cell formation, radiation necrosis, and vascular structural changes. Therefore, we should carefully examine pathological findings at recurrence. In this report, we analyzed MGMT promoter status, the MIB-1 index, and the pathology of tumor samples at the first (primary tumor) and second (recurrent tumor) surgeries and clarified prognostic factors in patients with recurrent cases. In the multivariate analysis, we showed that MIB-1 indexes at the time of the second surgery (p = 0.004) persisted as a significant independent prognostic factor in survival of patients with recurrent glioblastoma.Keywords
This publication has 25 references indexed in Scilit:
- Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive casesNeurosurgical Review, 2011
- Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastomaOncology Reports, 2010
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3The Lancet Oncology, 2008
- Prognostic Factors for Survival in Adult Patients With Recurrent Glioma Enrolled Onto the New Approaches to Brain Tumor Therapy CNS Consortium Phase I and II Clinical TrialsJournal of Clinical Oncology, 2007
- Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patientsActa Neurochirurgica, 2007
- Role of MIB1 in Predicting Survival in Patients with GlioblastomasJournal of Neuro-Oncology, 2005
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic valueJournal of Neurosurgery, 1997